310 related articles for article (PubMed ID: 29731479)
1. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer.
Yanai A; Itoh M; Hirakawa H; Yanai K; Tashiro M; Harada R; Yoshikawa A; Yamamoto S; Ohuchi N; Ishida T
Tohoku J Exp Med; 2018 May; 245(1):13-19. PubMed ID: 29731479
[TBL] [Abstract][Full Text] [Related]
2. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.
Wang CL; MacDonald LR; Rogers JV; Aravkin A; Haseley DR; Beatty JD
AJR Am J Roentgenol; 2011 Aug; 197(2):W247-55. PubMed ID: 21785049
[TBL] [Abstract][Full Text] [Related]
3. A preliminary report of breast cancer screening by positron emission mammography.
Yamamoto Y; Tasaki Y; Kuwada Y; Ozawa Y; Inoue T
Ann Nucl Med; 2016 Feb; 30(2):130-7. PubMed ID: 26586370
[TBL] [Abstract][Full Text] [Related]
4. High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer.
Berg WA; Weinberg IN; Narayanan D; Lobrano ME; Ross E; Amodei L; Tafra L; Adler LP; Uddo J; Stein W; Levine EA;
Breast J; 2006; 12(4):309-23. PubMed ID: 16848840
[TBL] [Abstract][Full Text] [Related]
5. Imaging sensitivity of dedicated positron emission mammography in relation to tumor size.
Eo JS; Chun IK; Paeng JC; Kang KW; Lee SM; Han W; Noh DY; Chung JK; Lee DS
Breast; 2012 Feb; 21(1):66-71. PubMed ID: 21871801
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
[TBL] [Abstract][Full Text] [Related]
7.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.
Kalinyak JE; Berg WA; Schilling K; Madsen KS; Narayanan D; Tartar M
Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):260-75. PubMed ID: 24085500
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
[TBL] [Abstract][Full Text] [Related]
10. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
11. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
12. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
14. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG.
Murthy K; Aznar M; Thompson CJ; Loutfi A; Lisbona R; Gagnon JH
J Nucl Med; 2000 Nov; 41(11):1851-8. PubMed ID: 11079494
[TBL] [Abstract][Full Text] [Related]
15. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer.
Berg WA; Madsen KS; Schilling K; Tartar M; Pisano ED; Larsen LH; Narayanan D; Kalinyak JE
AJR Am J Roentgenol; 2012 Jan; 198(1):219-32. PubMed ID: 22194501
[TBL] [Abstract][Full Text] [Related]
18. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
Jo JE; Kim JY; Lee SH; Kim S; Kang T
Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
[TBL] [Abstract][Full Text] [Related]
19. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
20. The current status of positron emission mammography in breast cancer diagnosis.
Kalles V; Zografos GC; Provatopoulou X; Koulocheri D; Gounaris A
Breast Cancer; 2013 Apr; 20(2):123-30. PubMed ID: 23239242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
